Amyris, Inc. (AMRS)
Chart Events
Performance Outlook
| Previous Close | 2.4200 |
| Open | 2.5100 |
| Bid | 2.2900 x 29200 |
| Ask | 2.3500 x 27000 |
| Day's Range | 2.1700 - 2.5960 |
| 52 Week Range | 1.4700 - 17.4200 |
| Volume | |
| Avg. Volume | 6,005,585 |
| Market Cap | 819.916M |
| Beta (5Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5060 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
AMYRIS PARTICIPATES IN INVESTOR CONFERENCES ON MAY 23, 24 AND 25, 2022
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that management is participating in fireside chats at the following investor conferences this week:
- PR Newswire
AMYRIS TO PARTICIPATE AT MAY INVESTOR CONFERENCES
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced that management will participate in fireside chats at the following upcoming investor conferences.
- Motley Fool
Better Buy: Gingko Bioworks vs. Amyris
Not long ago, Amyris and Gingko Bioworks were stock-market darlings, but the rout in tech stocks this year has been especially tough on these two. Shares of this synthetic biology start-up shot higher following its stock-market debut last year. The good times didn't last long, though, and now Gingko Bioworks stock is down more than 80% from its all-time high.
